Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
Researchers reached this conclusion after reviewing data on more than 30,000 people.
European and U.S. guidelines recommend that all those with cirrhosis undergo biannual screening for liver cancer.
People living with HIV are also facing cancer as they age.
Even positive breaking news looks different to people who know the reality of a hard-to-treat cancer.
Study in China sees an association with several cancer types, especially gastrointestinal malignancies.
Four things you should know to be #HepAware.
The drug is still associated with a lower liver cancer rate than Baraclude.
A quick overview of Hep Magazine’s reporting on the 53rd International Liver Congress in Vienna
Tenofovir was associated with a lower risk of hepatocellular carcinoma, but this might be related to other factors as well.
Clinical trials often exclude key patient populations, including children and people living with HIV or hepatitis B or C.
People with HIV who have higher viral load and worse immune function appear to be at higher risk for hepatocellular carcinoma.
Researchers compared liver-related death rates among Mexicans, Puerto Ricans and Cubans.
A third of patients taking neoadjuvant Opdivo had complete responses in an early analysis.
Cabometyx is the third liver cancer drug approved in the past six months.
Shawne Jabonero Lopes, DACM, LAc, shares her family’s liver health story.
A research team has sought to address the critical lack of treatment guidelines for addressing HIV’s complex effects on aging.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.